Advisers squabble over Mylan's desire for Perrigo; Benitec downsizes its IPO plans;

@FierceBiotech: FierceBiotech Radio on Amarin's First Amendment crusade, Martin Shkreli's Twitter, and Kim Kardashian's Instagram. Listen/Subscribe | Follow @FierceBiotech

@JohnCFierce: California cutbacks: Boston Sci to close two facilities, Abbott cuts 160+ employees. FierceMedicalDevices article | Follow @JohnCFierce

@DamianFierce: ICYMI: A wonderfully stern FDA official parses Kim Kardashian's Instagram. Letter | Follow @DamianFierce

> Proxy advisers are arguing over whether Mylan ($MYL) shareholders should support the company's efforts to acquire Perrigo ($PRGO) for around $200 per share. News

> Benitec Biopharma has scaled back its IPO ambitions, planning to raise just $15 million, a 41% reduction on its earlier plans. Story

> Water Street won FDA approval for the antibiotic Cefazolin, developed in collaboration with Baxter ($BAX). More

Medical Device News

@FierceMedDev: Roche shells out up to $425M for superbug testing outfit. FierceDiagnostics news | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Google joins forces with Dexcom for miniaturized glucose monitor. Article | Follow @VarunSaxena2

@EmilyWFierce: NICE plots takeover of England's Cancer Drugs Fund. FiercePharma article | Follow @EmilyWFierce

> NOWDiagnostics gets FDA blessing for one-step pregnancy test. News

> Roche deploying smartphone app to monitor patients during clinical trial of its Parkinson's med. Report

> NIH study sees little benefit to added fetal ECG monitoring during birth. Story

Pharma News

@FiercePharma: China FDA issues software guidelines on medical devices effective this month. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: Sun U.S. sales gut-kicked by supply constraints as it works on FDA concerns at Halol plant. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Biogen touts new Eloctate data as next-gen hemophilia rivals near the scene. FiercePharmaMarketing article | Follow @CarlyHFierce

> Novo says new U.S. plant may be best bet to offset the FX bite. More

> Shire raise its $30B Baxalta bid? It's going to need some details first. Article

> Takeda Actos settlement seems shaky as plaintiffs give it the sniff test. Story

> NICE plots takeover of England's Cancer Drugs Fund. Report

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.